newsEmpagliflozin trial halted after successful outcome in chronic kidney disease21 March 2022 | By European Pharmaceutical ReviewAn early halt has been called to a major kidney drug trial following positive results for patients with chronic kidney disease (CKD).
newsPotential for a new one-and-done COVID-19 treatment18 March 2022 | By Mandy Parrett (European Pharmaceutical Review)Investigational drug Lambda reduced risk of COVID-19-related death in one of the largest studies of its kind to date.
newsAbbVie’s preventative migraine treatment atogepant (Qulipta™) shows promise16 March 2022 | By Mandy Parrett (European Pharmaceutical Review)AbbVie releases promising results from its Phase III trial of atogepant (Qulipta™) for preventative treatment of chronic migraine.
newsKisqali increases overall survival in advanced breast cancer patients by 12 months10 March 2022 | By European Pharmaceutical ReviewKisqali plus letrozole achieved a median overall survival (OS) of over five years (63.9 months), with OS benefit increasing over time, according to newly published data.
articleGalenic software implementation on a rotary tablet press: IMAGO and its functionalities3 March 2022 | By Caterina Funaro (IMA), Federica Giatti (IMA Active), FS Consoli (IMA), Leo Di Carlo (IMA), Marco Minardi (IMA), Nicola Pistillo (IMA)In this article by IMA, discover how IMAGO software installed on rotary tablet presses supports scientists during tablet manufacturing, providing critical insights into powders.
articlePrioritising bold innovation throughout the pandemic and beyond22 February 2022 | By Chinmay BhattFollowing his first full year as Managing Director UK, Ireland & Nordics for Novartis Pharmaceuticals, healthcare leader Chinmay Bhatt shares his learnings from the pandemic and reflects on what’s next.
newsDARWIN EU® Coordination Centre to integrate real-world evidence into medicines regulation10 February 2022 | By Hannah Balfour (European Pharmaceutical Review)EMA will establish the DARWIN EU® Coordination Centre to develop and manage a network of real-world healthcare data sources across the EU.
articleThe microbiome: unlocking the Fourth Industrial (Bio) Revolution4 February 2022 | By Anthony Finbow (Eagle Genomics)The impending ‘Bio Revolution’, with the microbiome at its foundation, offers ground-breaking solutions and a wealth of opportunity in data science and bioinformatics, explains Anthony Finbow of Eagle Genomics.
newsNew strategy could improve generic drug quality assessments10 January 2022 | By Hannah Balfour (European Pharmaceutical Review)Population pharmaceutical quality assessment could be used to improve the quality consistency of generic drugs, suggests study.
articleEnabling impactful breakthroughs and therapies23 December 2021 | By Azenta Life SciencesLinda De Jesus, Senior Vice President and Chief Commercial Officer at Azenta Life Sciences highlights the benefits of uniting and focusing efforts solely for the life sciences sector.
whitepaperApplication note: Comprehensive fractionation of herbal medicine components by PDA-ELSD-triggered preparative LC22 December 2021 | By ShimadzuThis article introduces a comprehensive fractionation method for both UV absorbing and non-UV absorbing compounds.
whitepaperApplication note: Taxonomic traceability for bacterial and fungal entries in Accugenix® reference databases22 December 2021 | By Charles RiverWhen you are reviewing bacterial and fungal isolates, do you appreciate that the names given to these organisms are regulated?
whitepaperProduct hub: 3P® connect EM-BODY connectivity21 December 2021 | By bioMérieux3P CONNECT is your EM partner for data compliance and process efficiency, for reliable decision making and taking control of your EM.
newsCilta-cel achieves progression-free survival in multiple myeloma patients15 December 2021 | By Anna Begley (European Pharmaceutical Review)In the Phase Ib/II trial, cilta-cel achieved minimal residual disease negativity in 92 percent of patients and improved survival.
newsmRNA-1010 quadrivalent flu vaccine shows promise in Phase I study14 December 2021 | By Anna Begley (European Pharmaceutical Review)Moderna's quadrivalent flu vaccine mRNA-1010 boosted titres against all four strains 29 days after vaccination in young and older adults.
